WO2009086526A3 - Methods for enhancing muscle performance and tone - Google Patents

Methods for enhancing muscle performance and tone Download PDF

Info

Publication number
WO2009086526A3
WO2009086526A3 PCT/US2008/088466 US2008088466W WO2009086526A3 WO 2009086526 A3 WO2009086526 A3 WO 2009086526A3 US 2008088466 W US2008088466 W US 2008088466W WO 2009086526 A3 WO2009086526 A3 WO 2009086526A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
subject
tone
exercise
muscle performance
Prior art date
Application number
PCT/US2008/088466
Other languages
French (fr)
Other versions
WO2009086526A2 (en
Inventor
Ronald M. Evans
Vihang A. Narkar
Reuben J. Shaw
Michael Downes
Ruth T. Yu
Original Assignee
The Salk Institute For Biological Studies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2007/089124 external-priority patent/WO2008083330A2/en
Application filed by The Salk Institute For Biological Studies filed Critical The Salk Institute For Biological Studies
Priority to EP08866040A priority Critical patent/EP2234622A4/en
Priority to AU2008345009A priority patent/AU2008345009A1/en
Priority to JP2010540930A priority patent/JP2011507970A/en
Priority to US12/810,123 priority patent/US9192601B2/en
Priority to CA2710764A priority patent/CA2710764A1/en
Publication of WO2009086526A2 publication Critical patent/WO2009086526A2/en
Publication of WO2009086526A3 publication Critical patent/WO2009086526A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

Agonists of AMP-activated protein kinase (AMPK) improve exercise and modify energy metabolism in a subject A combination of AMPK and peroxisome proliferator-activated receptor (PPAR) delta agonists may also be used to improve exercise performance in a subject Methods for identifying substance-enhanced exercise performance in a subject, and methods for identifying compounds that affect the interaction of PPAR6 with exercise-induced kinases are also disclosed.
PCT/US2008/088466 2006-12-29 2008-12-29 Methods for enhancing muscle performance and tone WO2009086526A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP08866040A EP2234622A4 (en) 2007-12-28 2008-12-29 Methods for enhancing muscle performance and tone
AU2008345009A AU2008345009A1 (en) 2007-12-28 2008-12-29 Methods for enhancing muscle performance and tone
JP2010540930A JP2011507970A (en) 2007-12-28 2008-12-29 Methods for improving muscle capacity and tension
US12/810,123 US9192601B2 (en) 2006-12-29 2008-12-29 Methods for enhancing muscle performance and tone
CA2710764A CA2710764A1 (en) 2007-12-28 2008-12-29 Methods for enhancing muscle performance and tone

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
PCT/US2007/089124 WO2008083330A2 (en) 2006-12-29 2007-12-28 Methods for enhancing exercise performance
US11/966,851 US20080187928A1 (en) 2006-12-29 2007-12-28 Methods for enhancing exercise performance
US11/966,851 2007-12-28
USPCT/US07/089124 2007-12-28
US8084108P 2008-07-15 2008-07-15
US61/080,841 2008-07-15

Publications (2)

Publication Number Publication Date
WO2009086526A2 WO2009086526A2 (en) 2009-07-09
WO2009086526A3 true WO2009086526A3 (en) 2009-09-03

Family

ID=40825106

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/088466 WO2009086526A2 (en) 2006-12-29 2008-12-29 Methods for enhancing muscle performance and tone

Country Status (5)

Country Link
EP (1) EP2234622A4 (en)
JP (1) JP2011507970A (en)
AU (1) AU2008345009A1 (en)
CA (1) CA2710764A1 (en)
WO (1) WO2009086526A2 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2114396A4 (en) 2006-12-29 2010-03-10 Salk Inst For Biological Studi Methods for enhancing exercise performance
EP2409152A4 (en) * 2009-03-20 2012-10-17 Salk Inst For Biological Studi Methods for modulating circadian rhythms
KR101698201B1 (en) * 2010-05-20 2017-01-19 (주)뉴트리 Composition for increasing muscle mass, anti-fatigue and enhancing exercise performance comprising panduratin derivatives or Boesenbergia pandurata extract
EP2612669A4 (en) 2010-08-31 2014-05-14 Snu R&Db Foundation Use of the fetal reprogramming of a ppar agonist
US20140147431A1 (en) * 2010-09-20 2014-05-29 The Regents Of The University Of California Compositions and Methods for Modulating Desnutrin-Mediated Adipocyte Lipolysis
EP2554182A1 (en) * 2011-08-03 2013-02-06 Universitat Pompeu-Fabra Mammal sestrins in the treatment of muscle wasting
US20140186306A1 (en) * 2012-09-28 2014-07-03 Paul Ronald Plante Novel ampk agonist compositions and methods of use
WO2014165827A1 (en) 2013-04-05 2014-10-09 Salk Institute For Biological Studies Ppar agonists
EP3756661A1 (en) * 2013-09-09 2020-12-30 vTv Therapeutics LLC Use of a ppar-delta agonist for treating muscle atrophy
WO2016057656A1 (en) 2014-10-08 2016-04-14 Mitobridge, Inc. Ppar-delta agonists for use for treating mitochondrial, vascular, muscular, and demyelinating diseases
WO2016057322A1 (en) 2014-10-08 2016-04-14 Salk Institute For Biological Studies Ppar agonists and methods of use thereof
EA037371B1 (en) 2015-10-07 2021-03-19 Митобридж, Инк. Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
WO2017180818A1 (en) 2016-04-13 2017-10-19 Mitobridge, Inc. Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
SG11202103984WA (en) 2018-10-23 2021-05-28 Japan Science & Tech Agency PPARd activator
WO2023147309A1 (en) 2022-01-25 2023-08-03 Reneo Pharmaceuticals, Inc. Use of ppar-delta agonists in the treatment of disease

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040259948A1 (en) * 2003-01-10 2004-12-23 Peter Tontonoz Reciprocal regulation of inflammation and lipid metabolism by liver X receptors
US20050233328A1 (en) * 2001-12-03 2005-10-20 Constance Berghs Methods of identifying compounds that modulate protein activity
US20070015686A1 (en) * 2005-07-07 2007-01-18 Heuer Marvin A Dietary supplement for enhancing skeletal muscle mass, decreasing muscle protein degradation, downregulation of muscle catabolism pathways, and decreasing catabolism of muscle cells
US20070203083A1 (en) * 2003-06-13 2007-08-30 Mootha Vamsi K Methods Of Regulating Metabolism And Mitochondrial Function
US20070248698A1 (en) * 2003-12-30 2007-10-25 Md Bioalpha Co., Ltd., Obesity and Metabolic Syndrome Treatment with Tanshinone Derivatives Which Increase Metabolic Activity
US20070265223A1 (en) * 2006-03-10 2007-11-15 Ikaria, Inc. Compositions and methods of enhancing survivability and reducing injury of cells, tissues, organs, and organisms under hypoxic or ischemic conditions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001269785A1 (en) * 2000-06-09 2001-12-17 Brigham Young University Method of treatment of obesity and paralyzed muscle and ergogenic aids
EP2114396A4 (en) * 2006-12-29 2010-03-10 Salk Inst For Biological Studi Methods for enhancing exercise performance

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050233328A1 (en) * 2001-12-03 2005-10-20 Constance Berghs Methods of identifying compounds that modulate protein activity
US20040259948A1 (en) * 2003-01-10 2004-12-23 Peter Tontonoz Reciprocal regulation of inflammation and lipid metabolism by liver X receptors
US20070203083A1 (en) * 2003-06-13 2007-08-30 Mootha Vamsi K Methods Of Regulating Metabolism And Mitochondrial Function
US20070248698A1 (en) * 2003-12-30 2007-10-25 Md Bioalpha Co., Ltd., Obesity and Metabolic Syndrome Treatment with Tanshinone Derivatives Which Increase Metabolic Activity
US20070015686A1 (en) * 2005-07-07 2007-01-18 Heuer Marvin A Dietary supplement for enhancing skeletal muscle mass, decreasing muscle protein degradation, downregulation of muscle catabolism pathways, and decreasing catabolism of muscle cells
US20070265223A1 (en) * 2006-03-10 2007-11-15 Ikaria, Inc. Compositions and methods of enhancing survivability and reducing injury of cells, tissues, organs, and organisms under hypoxic or ischemic conditions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP2234622A4 *

Also Published As

Publication number Publication date
AU2008345009A1 (en) 2009-07-09
WO2009086526A2 (en) 2009-07-09
EP2234622A4 (en) 2011-03-09
EP2234622A2 (en) 2010-10-06
CA2710764A1 (en) 2009-07-09
JP2011507970A (en) 2011-03-10

Similar Documents

Publication Publication Date Title
WO2009086526A3 (en) Methods for enhancing muscle performance and tone
LTPA2017011I1 (en) Antibody against PDGFR-alpha for use in the treatment of tumors
WO2010129923A8 (en) Patterned heat management material
PL2364988T3 (en) Stable NAD/NADH derivatives
EP1954214A4 (en) Methods, devices, and kits for treating mitral valve prolapse
EP2192134A4 (en) Photosensitive composition, pattern-forming method using the photosensitive composition, and compound used in the photosensitive composition
WO2008083330A3 (en) Methods for enhancing exercise performance
BRPI0718315A2 (en) APPLIANCE AND DISPERSION OF POWDER, METHOD OF MANUFACTURING AND USING THE APPLIANCE, AND COMPONENTS THAT MAY BE USED IN THE APPLIANCE AND OTHER DEVICES.
WO2007087139A3 (en) MESENCHYMAL STEM CELLS EXPRESSING TNF-α RECEPTOR
FI20085213A (en) The pigment particle composition, the process for its preparation and its use
IL195821A0 (en) Cycloalkanopyrrolocarbazole derivatives and the use thereof as parp, vegfr2 and mlk3 inhibitors
EP1906934A4 (en) Daily dosage regimen for treating diabetes, obsity, metabolic syndrome and polycystic ovary syndrome
WO2006070023A3 (en) Method for reversing multiple resistance in animal cells
IL198088A (en) Heterocyclic compounds for use in extending life span, improving and/or delaying worsening of one or more symptoms associated with senescence
WO2009052106A3 (en) Formulation to improve gastrointestinal function
EP2088140A4 (en) Dihydrazide compounds, preparation and uses thereof
GB2447328B (en) Orthopedic jig, pin and method
CA2657756C (en) Dry food to reduce dogs' appetites
EP2305803A4 (en) Thermostable 1,5-anhydroglucitol dehydrogenase, and method for measurement of 1,5-anhydroglucitol by using the same
PL379401A1 (en) Central heating and hot water furnace, particularly the wood- and wood chips-fired furnace
FI20060718A0 (en) The wood preservative
Gren-Eklund et al. Orientalia Suecana: An International Journal of indology, Iranian, Semitic and Turkic Studies
PL122543U1 (en) Holder for the elasticizing rope
Nakagawa Evaluation of the Nuss procedure using pre and postoperative CT index
Osta I and Translation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08866040

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2710764

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2010540930

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008345009

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2008866040

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2008345009

Country of ref document: AU

Date of ref document: 20081229

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 12810123

Country of ref document: US